Physician profile
Barbara E Smith
NPI 1598271835
$7,942.37
in general payments reported to CMS, 2019-2025
24 companies · $1,825 in 2025
The $1,825 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,370 · 2022: $1,758 · 2023: $1,829 · 2024: $1,161 · 2025: $1,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,368 · Education: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,368.00 |
| Education | $446.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,483.53 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,055.76 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $979.91 | 2022-2025 | Ilumya |
| Janssen Biotech, INC. | $927.09 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $925.13 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $501.69 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $416.40 | 2021-2025 | |
| Lilly USA, LLC | $400.98 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $330.78 | 2022-2025 | Sotyktu |
| Ucb, INC. | $234.10 | 2021-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $210.82 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $122.78 | 2021-2024 | Jublia, Arazlo, Duobrii |
| Mayne Pharma Commercial LLC | $93.78 | 2023-2025 | |
| Sensus Healthcare, INC. | $42.19 | 2021 | |
| Arcutis Biotherapeutics, INC. | $35.24 | 2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $33.06 | 2025 | Sofdra |
| Incyte Corporation | $26.08 | 2023 | Opzelura |
| Lnhc, INC | $22.54 | 2025 | Zelsuvmi |
| Biofrontera INC. | $20.77 | 2025 | |
| Vyne Pharmaceuticals INC. | $20.08 | 2021 | |
| Dermira, INC. | $16.15 | 2021 | |
| Verrica Pharmaceuticals INC. | $16.12 | 2023 | Ycanth |
| Dermavant Sciences, INC. | $14.00 | 2022 | |
| Organon LLC | $13.39 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.